Everything below concerns research compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
The complete blood count is interpreted by comparing the output to reference ranges, which represent the results found in 95% of apparently healthy people. Based on a statistical normal distribution, the tested samples' ranges vary with sex and age. On average, adult females have lower hemoglobin, hematocrit, and red blood cell count values than males; the difference lessens, but is still present, after menopause. CBC results for children and newborn babies differ from those of adults. Newborns' hemoglobin, hematocrit, and red blood cell count are extremely high to compensate for low oxygen levels in the womb and the high proportion of fetal hemoglobin, which is less effective at delivering oxygen to tissues than mature forms of hemoglobin, inside their red blood cells. The MCV is also increased, and the white blood cell count is elevated with a preponderance of neutrophils. The red blood cell count and related values begin to decline shortly after birth, reaching their lowest point at about two months of age and increasing thereafter. The red blood cells of older infants and children are smaller, with a lower MCH, than those of adults. In the paediatric white blood cell differential, lymphocytes often outnumber neutrophils, while in adults neutrophils predominate. Other differences between populations may affect the reference ranges: for example, people living at higher altitudes have higher hemoglobin, hematocrit, and RBC results, and people of African heritage have lower white blood cell counts on average.
=== Early life, start of career and Basel === Photaki was born in Corinth in 1921 and finished her secondary education at the 2nd Girls' Gymnasium of Athens in 1938. In the same year she enrolled at the Department of Chemistry in the University of Athens, where she specialised in Organic chemistry under the mentorship of Leonidas Zervas. Her studies were interrupted during the Axis occupation of Greece when the Laboratory of Organic Chemistry was destroyed and Zervas was imprisoned as a member of the Greek Resistance. Photaki was finally awarded her degree summa cum laude in 1946 and subsequently continued her postgraduate studies under Zervas, earning her PhD in 1950 with a dissertation regarding glucosamine. Concurrently, she held a paid laboratory assistant position at the university already from 1943, carrying on as a research assistant until 1953. In 1953, Photaki was awarded a scholarship to conduct research in Basel after examinations by the Greek State Scholarships Foundation. At the University of Basel she worked in the Laboratory of Organic Chemistry, at the time headed by Nobel laureate Tadeusz Reichstein. For the first two years of her stay (1953–1955) she was part of the Max Brenner research group, later moving as an independent scientific associate of Hans Erlenmeyer. Upon returning to Greece, she initially worked at the biochemical lab of the Evangelismos Hospital before being invited by Zervas to the nascent National Hellenic Research Foundation (NHRF) which he had helped found.
== Development == Humans are born with a set number of heart muscle cells, or cardiomyocytes, which increase in size as the heart grows larger during childhood development. Evidence suggests that cardiomyocytes are slowly turned over during aging, but less than 50% of the cardiomyocytes present at birth are replaced during a normal life span. The growth of individual cardiomyocytes not only occurs during normal heart development, it also occurs in response to extensive exercise (athletic heart syndrome), heart disease, or heart muscle injury such as after a myocardial infarction. A healthy adult cardiomyocyte has a cylindrical shape that is approximately 100μm long and 10–25μm in diameter. Cardiomyocyte hypertrophy occurs through sarcomerogenesis, the creation of new sarcomere units in the cell. During heart volume overload, cardiomyocytes grow through eccentric hypertrophy. The cardiomyocytes extend lengthwise but have the same diameter, resulting in ventricular dilation. During heart pressure overload, cardiomyocytes grow through concentric hypertrophy. The cardiomyocytes grow larger in diameter but have the same length, resulting in heart wall thickening.
The type II and XI collagenopathies are a group of disorders that affect connective tissue, the tissue that supports the body's joints and organs. These disorders are caused by defects in type II or type XI collagen. Collagens are complex molecules that provide structure, strength, and elasticity to connective tissue. Type II and type XI collagen disorders are grouped together because both types of collagen are components of the cartilage found in joints and the spinal column, the inner ear, and the jelly-like substance that fills the eyeball (the vitreous). The type II and XI collagenopathies result in similar clinical features.
Sources: en.wikipedia.org
The Kingdom of Naples passed to Charles' eight-year-old son, Ferdinand IV of the Two Sicilies, under the tutelage of a regency council dominated by Tanucci. This allowed the continuation of the minister's reform policies, particularly in the ecclesiastical field. This culminated in the expulsion of the Jesuits from the Kingdom in 1769 and the forfeiture of their property. Even after Ferdinand came of age, Tanucci remained in office, but in 1774 he was exonerated at the instigation of Queen Maria Carolina of Austria, who wanted to bring Naples into the Austrian sphere of influence. However, the king continued season, pandering to the Neapolitan Enlightenment (Ferdinando Galiani, Antonio Genovesi and Gaetano Filangeri). During this period Calabria experienced major natural disasters, accompanied by social and economic changes: the plague arrived in 1743, striking Reggio Calabria and its surroundings from Messina, delaying the compilation of the cadastre onciario by local universities. The earthquake of 1783 struck southern Calabria killing some 50,000 and destroying Reggio, which was rebuilt according to more rational and linear architectural criteria. TKing Ferdinand IV sent the prince of Strongoli, Francesco Pignatelli, to cope with emergencies in the earthquake-affected areas. To finance the immense reconstruction expenses, he established the Cassa Sacra, to manage funds derived from the expropriation of abolished ecclesiastical property and monasteries.
In January 2023, Futurism broke the story that CNET had been using an undisclosed internal AI tool to write at least 77 of its stories; after the news broke, CNET posted corrections to 41 of the stories. In April 2023, Die Aktuelle published an AI-generated fake interview of Michael Schumacher. In May 2024, Futurism noted that a content management system video by AdVon Commerce, which had used generative AI to produce articles for many of the aforementioned outlets, appeared to show that they "had produced tens of thousands of articles for more than 150 publishers". In 2025, a report from the American Sunlight Project stated that Pravda network was publishing as many as 10,000 articles a day, and concluded that much of this content aimed to push Russian narratives into large language models through their training data. In June 2024, Reuters Institute published its Digital News Report for 2024. In a survey of people in America and Europe, Reuters Institute reports that 52% and 47% respectively are uncomfortable with news produced by "mostly AI with some human oversight", and 23% and 15% respectively report being comfortable. 42% of Americans and 33% of Europeans reported that they were comfortable with news produced by "mainly human with some help from AI". The results of global surveys reported that people were more uncomfortable with news topics including politics (46%), crime (43%), and local news (37%) produced by AI than other news topics. A 2025 Pew Research Survey found roughly half of all U.S.
Domino's Pizza Israel was founded in 1990, and opened their first branch in 1993. They are operated by Elgad Pizza. As of August 2014, there are 33 branches throughout the state. There are four kosher franchises. The rights to own, operate, and franchise branches of the chain in Australia, New Zealand, France, Belgium, the Netherlands, Monaco, Luxembourg, Germany, Japan, Malaysia, Singapore, Taiwan and Cambodia are currently owned by Australian Domino's Pizza Enterprises, having bought the master franchises from the parent company in 1993 (Australian and New Zealand franchises). The Australian company also acquired several European and Asian franchises between 2013 and 2022. It acquired the Danish operations in 2019 but liquidated them in 2023. The master franchises for the UK and Ireland were purchased in 1993 by the British publicly listed Domino's Pizza Group (DPG), which acquired the master franchise for Germany in 2011, and Switzerland, Liechtenstein, and Luxembourg in August 2012 by buying the Swiss master franchise holder, with an option to acquire the Austrian master franchise as well. DPG opened its first Swedish location near the Mobilia shopping mall in Malmö in December 2016; three years later, in 2019, they announced that they would be selling all of their current businesses in the country. In Latin America, the first franchise was opened in 1988 in Colombia. During the next years, Domino's Pizza started operations in Mexico, Guatemala (1989), Chile (1991), Venezuela (1992), Dominican Republic (1993), Ecuador and Peru (1995).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.